Lumizyme
Lumizyme ingredients
| Active ingredient | Strength |
|---|---|
| Alglucosidase Alfa | 5 mg/mL |
What Lumizyme is used for
The FDA lists the approved uses on the official label (below). In the EU, alglucosidase alfa is approved as Myozyme for:
Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-alpha-glucosidase deficiency). In patients with late-onset Pompe disease the evidence of efficacy is limited.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lumizyme
- Generic name
- Alglucosidase alfa
- Made by
- Genzyme Corporation
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- Drug class
- Hydrolytic Lysosomal Glycogen-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA125291
- On the US market since
- 2010
Official information
- Lumizyme prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Alglucosidase alfa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lumizyme?
Lumizyme (Alglucosidase alfa) is a specialist medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Lumizyme?
Lumizyme contains Alglucosidase Alfa (5 mg/mL).
Is Lumizyme approved in Europe?
The same active substance is approved in the EU as Myozyme.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA